baber/WOPTO huggingface dataset:
Patent NZ-240573-A (NZ)
Title: Powder inhaler: metering drum between mouthpiece and supply chamber
Inventor: GUPTE ARUN RAJARAM
IPC: A61M13/00
Filed: 1991-11-13
Abstract: The invention relates to a propellant-free inhalation device with a supply of pulverized medical substance in a supply chamber, which has a rotatable dosing means with one or more dosing chambers to receive in one defined position the dose of the medical substance to be inhaled from the supply chamber and to discharge the dose in another position. The inhalation device further is provided with a mouthpiece for active inhalation and an air channel to distribute the dose discharged from the dosing chamber in the flow of breathing air.
Patent NZ-243904-A (NZ)
Title: Absorbent article comprising a core layer of a foamed polymeric material
Inventor: YOUNG GERALD ALFRED
IPC: A61F13/56
Filed: 1992-08-11
Abstract: Disclosed are absorbent articles, such as diapers, for the management of incontinence. Such articles utilize in their absorbent cores an fluid acquisition/distribution component and a fluid storage/redistribution component maintained in fluid communication with the acquisition/distribution component. The fluid acquisition/distribution component can be any porous hydrophilic, e.g., fibrous or foam-based, material which will provide an initial Fluid Acquisition Rate of at least 2 mL of synthetic urine per second and will also preferably provide a 30-minute Vertical Wicking Height of at least 2 cm. The fluid storage/redistribution component comprises a hydrophilic, flexible, open-celled polymeric foam having a free absorbent capacity of at least about 12 mL of synthetic urine per gram of dry foam and an absorbent capacity under a 5.1 kPa confining pressure which is at least 5% of this free capacity. Preferred fluid acquisition/distribution component materials comprise chemically stiffened, twisted, curled cellulosic fibers. Preferred fluid storage/redistribution component materials comprise absorbent foams prepared by polymerizing a high internal phase emulsion (HIPE).
Patent NZ-279044-A (NZ)
Title: Detecting methylthioadenosine phosphorylase deficiency
Inventor: NOBORI TSUTOMU
IPC: C12Q1/68
Filed: 1994-12-22
Abstract: Catalytically active and inactive MTAse (methyladenosine phosphatase) are detected in mammalian cells by (1) treating cells suspected of being MTAse deficient with an oligonucleotide probe that hybridises specifically to an MTAse encoding nucleic acid and (2) detecting whether such nucleic acid is present. Also new are (1) isolated polynucleotides (I) encoding MTAse, (2) recombinant expression vectors contg. (I) or its fragments, (3) MTAse (or its fragments) expressed from these vectors or prepd. synthetically, (4) antibodies (Ab) raised against MTAse or its fragment.
Patent NZ-302055-A (NZ)
Title: Heterocyclic inhibitors of microsomal triglyceride transfer protein
Inventor: WETTERAU JOHN R
IPC: C07D217/22
Filed: 1997-08-20
Abstract: Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure I wherein R1  is a fluorenyl -type group of formula B, C or D where the moieties are as defined in the disclosure, R5 is selected from standard substituents, R6 is H or optionally substituted alkyl or alkenyl and Q is C(O) or S(O)2 , and N-oxides and pharmaceutically acceptable salts thereof.
Patent NZ-326345-A (NZ)
Title: Composition containing diosgenin
Inventor: CLAYTON PAUL RODNEY
IPC: A61K31/4415
Filed: 1997-01-10
Abstract: A composition for the treatment or prevention of osteoporosis by the administering to a subject in need thereof therapeutically effective amounts of diosgenin, vitamin K and vitamin D and optionally a therapeutically effective amount of vitamin B6 and/or vitamin A is described.
Patent NZ-331771-A (NZ)
Title: Lytic peptides with amphipathic alpha helices and positively charged N- or C-terminal, methods of activation/inactivation, compositions and methods of treatment are also included
Inventor: RIVETT DONALD EDWARD
IPC: A61K47/48
Filed: 1997-03-13
Abstract: A molecule which has lytic activity, comprising an amphipathic á-helical peptide in which the hydrophilic face of the á-helix comprises at least two amino acids each of which has a net positive charge, and in which the molecule has an overall positive charge of two. The amphipathic á-helix has the general formula 1 or 2 where Ù is glycine; hydrophobic amino acid including but not limited to alanine, isoleucine, leucine, valine and norleucine or Ö Ö phenylalanine, tryptophan, tyrosine, a nonnaturally occurring aromatic amino acid, or a synthetic aromatic residue; C is cysteine or cysteine amide P is proline Hypro is hydroxyproline Z is an amino acid which is not negatively charged, or is either crosslinked agent, or a blocking agent and X is a sequence of hydrophilic amino acids, at least one of which is a basic amino acid and where C or Z may be at either end of the peptide not at both ends. Further claimed is the method of modulating lytic activity of these molecules, and the use to treat cancer, HIV manifestation, viral infection and microbial infection.
Patent NZ-332633-A (NZ)
Title: Sulfonamide-substituted fused 5-membered ring compounds and their use in treating gastrointestinal ulcers and cardiovascular and diarrheal disorders
Inventor: BRENDEL JOACHIM
IPC: C07D213/42
Filed: 1998-11-06
Abstract: The compounds of formula I have specific blocking action on a potassium channel that is opened by cAMP.  R(1) and R(2) are independently H, CF3, or an alkyl group; or R(2) and R(9) together are a bond; or R(2) is OR(10a), if  X is CR(22)R(23)          where R(10a) is H, acetyl or an alkyl group. R(3)is R(10b)CnH2nNR(11) or R(10)bCnH2n, where a CH2 in CnH2n may be replaced by O, CO, S, SO, SO2 or NR(12a); (R(12a) is H, methyl or ethyl; R(10b)is methyl, cycloalkyl, CF3, C2F5 or C3F7; n is 0-10; R(11) is H or an alkyl; or R(10b) and R(11) are a bond); or R(3) together with R(4) is an alkylene chain which may be substituted. R(4) is R(13)-CrH2r,         where a group of CrH2r may be replaced by O, CH=CH, CO, O-CO, S NR(14) or CONR(14) or other group; (R(14) is H, alkyl, CyH2yOR(12b) or CyH2yNR(12b)2, where R(12b) is H, methyl or ethyl); and         where R(13) is a cycloalkyl, CH3, CF3, NR(15)R(16), CONR(15)R(16),         substituted or unsubstituted phenyl, a nitrogen-containing heterocycle or other group; (R(15) and R(16) are independently H or an alkyl, or together are a chain of methylene groups). R(5), R(6), R(7) and R(8) are independently H, a halogen, alkyl, cycloalkyl, CN, CF3, C2F5, C3F7, N3, NO2, phenyl, thienyl, furyl, a nitrogen-containing heterocycle or other group. X is CR(22)R(23), O, NR(24), S, SO or SO2        where R(22) and R(23) are independently H, CF3 or an alkyl group, and R(24) is H,        an alkyl or a substituted or unsubstituted phenyl.  The compounds or physiologically tolerable salts thereof, are used in a medicament for the prophylaxis and therapy of cardiovascular diseases, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal illnesses.
Patent NZ-334874-A (NZ)
Title: Derivatives of phenoxy acetic acid and phenoxymethyl tetrazole having anti-tumour activity
Inventor: DI DOMENICO ROBERTO
IPC: C07C49/83
Filed: 1999-03-26
Abstract: Compounds the general formula I and their use in the preparation of a medicament having MDM2 antagonistic activity and for the treatment of sarcomas wherein; the O-C(R1)(R2)-(CH2)p-A group can be in ortho, meta or para position, A is selected from COOH, -COO-(C1-C4)alkyl, CN or a group of formula II wherein, R' is hydrogen or (C1-C4)alkyl, or the group A-(CH2)p-C(R1)(R2) is selected from phenyl, benzyl or (indolyl)methyl, optionally substituted by R4 groups, p is 0, 1 or 2, R1 and R2 are independently selected from hydrogen or (C1-C8)alkyl or they form, together with the carbon atom to which they are linked, a (C3-C7)cycloalkyl group, R4 is from 0 to 2 substituents independently selected from chlorine, bromine, iodine, fluorine, linear or branched (C1-C8)alkyl, hydroxy, (C1-C4)alkoxy, (C1-C4)acyl groups, or the group III in formula I is a naphthyl group which may be in its turn substituted by R4 groups, n is an integer from 1 to 4, m is 0 or 1, B is selected from linear or branched C1-C10 alkyl, CO-C(R3)=CH-R, CH=C(R3)-CO-Ar, CO-CH(R3)-CH2-R or CO-CH(R3)-CH2-NR5R6 when m is 0 or is CH=C(R3)-CO-Ar when m is 1, R is selected from hydrogen, Ar or CO-Ar, R3 is hydrogen or a (C1-C8)alkyl group, R5 and R6 are independently a (C1-C4)alkyl group or they form, together with the nitrogen atom to which they are linked, a piperidino, piperazino, (C1-C8)alkylpiperazino, morpholino or thiomorpholino group, Ar is a phenyl group optionally substituted with from 1 to 3 groups independently selected from chlorine, bromine, iodine, fluorine, linear or branched (C1-C8)alkyl, hydroxy, (C1-C4)alkoxy, (C1-C4)acyl groups, stereoisomers thereof or salts thereof with pharmaceutically acceptable acids or bases.
Patent NZ-335546-A (NZ)
Title: An enzyme having S-adenosyl-L-homocysteine hydrolase AHCY-type activity; DNA sequence encoding this and antibody which binds to the enzyme
Inventor: HART DEREK NIGEL JOHN
IPC: C12N9/14
Filed: 1997-10-06
Abstract: An enzyme having S-adenosyl-L-homocysteine type (AHCY-type) activity.  Also disclosed is a method of determining, ex vivo, the modulatory potential of a compound on the enzyme.
Patent NZ-336382-A (NZ)
Title: Intranasal formulations for treating sexual disorders comprising Viagra or sildenafil mesylate in particular crystalline mono or dihydrate
Inventor: DUNN PETER JAMES
IPC: C07D487/04
Filed: 1999-06-21
Abstract: The sildenafil (Viagra) salt  sildenafil mesylate.  Intranasal pharmaceutical formulations for the treatment of erectile dysfunction including sildenal mesylate.
Patent NZ-337279-A (NZ)
Title: Rotor for electric motor
Inventor: SHIGA TSUHOSHI
IPC: H02K1/27
Filed: 1999-08-17
Abstract: A rotor 28 for an electric motor comprises a frame 29 made of a resin and a cylindrical yoke mounting portion 30, a base 31 covering one end side of yoke mounting portion 30 and a shaft supporting portion 32 located at the center of rotation of base 31.  Yoke mounting portion 30, base 31 and shaft supporting portion 32 are formed integrally with frame 29.  A rotor yoke 35 is provided on yoke mounting portion 30 and is divided into a plurality of unit yokes 36.  A plurality of rotor magnets 38 is provided on yoke mounting portion 30 along the rotor yoke 35.
Patent NZ-500438-A (NZ)
Title: Compositions containing a compound having kappa opioid agonist activity for treatment of pruritis (itchiness)
Inventor: FARRAR JOHN J
IPC: A61K31/22
Filed: 1998-06-19
Abstract: Anti-pruritic pharmaceutical formulations containing kappa agonist compounds and methods of prevention or treatment of pruritus in a mammal with the anti-pruritic formulations.
Patent NZ-502349-A (NZ)
Title: Polyethylene catalysts comprising an organoaluminium compound as a co-catalyst
Inventor: ASHTON DAVID JOHN
IPC: C08F4/657
Filed: 1998-07-22
Abstract: A high activity catalyst composition for the (co-)polymerisation of ethylene, optionally with an alpha olefin of 3 to 10 carbon atoms, comprising a catalyst precursor and an organoaluminium co-catalyst, wherein the catalyst precursor consists of: (i) a silica carrier material, having from 0.3 to 1.2 mmoles of OH groups per gram of silica, (ii) a dialkylmagnesium compound of the formula RMgR1, where R and R1 are the same or different C2-C12 alkyl groups, in an amount comprised between 0.5 to 1.5 mmoles of dialkylmagnesium per gram of silica, (iii) a tetraalkyl orthosilicate, in which the alkyl groups contain from 2 to 6 carbon atoms, in an amount comprised between 0.2 to 0.8 mmoles per gram of silica, (iv) a chlorinated compound (X) having the formula RnSiCl4-n, wherein each R is the same or different and is hydrogen or an alkyl group and n is an integer from 0 to 3, in an amount comprised between 0.2 to 4 mmoles of X per gram of silica, and (v) a titanium compound in an amount comprised between 0.3 to 1.5 mmoles per gram of silica.
Patent NZ-503030-A (NZ)
Title: Decorative pull tab container opening devices with images formed by local laser removal of coating layer
Inventor: STASIUK JOSEPH W
IPC: B65D17/347
Filed: 1998-08-26
Abstract: A container opening device, container lid (20), or can top with a decorated feature, or in the case of an opening device, a symbolically shaped pull tab (40) for attachment to a container to perform the dual functions of opening the container and decorating the container for equity, identification or promotional purposes. The pull tab (40) may open the container by acting as a lever which presses against a tear strip (30) in the container top (20) defined by a tear line (31) to separate the tear strip from the container top (20) and open the container (10). The pull tab (40) may perform a decorative and promotional function by having a decoration or a symbolic shape that is to be recognized as a picture, trademark, icon, character, or other symbolic item or logo. The decoration can be enhanced further by applying colour, printing, embossing and labels to the pull tab (40), lid (20) or container (10). The pull tab (40) or decoration can take the shape and design of corporate logos, trademarks, icons, etc. In an alternative embodiment, the pull tab may have a weakened portion so that a piece of the pull tab may be removable from the container as a token or memento.
Patent NZ-503669-A (NZ)
Title: Trivalent thrombin inhibitor comprising (S subsite blocking segment)-(S' subsite blocking segment)-(fibrinogen recognition exosite blocking segment)
Inventor: KONISHI YASUO
IPC: C07K14/815
Filed: 1997-10-15
Abstract: A thrombin inhibitor or a pharmaceutically acceptable salt thereof has the formula (I)   AS-Z-P wherein: AS is an S subsite blocking segment; P is a fibrinogen recognition exosite blocking segment and Z is a S' subsite blocking segment which links AS and P. The S' subsite blocking segment has the sequence:  Xaa-Gly-Yaa-Gly-bAla wherein: Xaa is a residue selected from glycine, L-alanine, D-alanine, 2-aminoisobutyric acid, L-a-aminobutyric acid, D-a-aminobutyric acid, L-norvaline, D-norvaline, L-norleucine, D-norleucine, L-cysteine, L-penicillamine, D-penicillamine, L-methionine, D-methionine, L-valine, D-valine, L-tert butylglycine, D-tert butylglycine, L-isoleucine, D-isoleucine, L-leucine, D-leucine, cyclohexylglycine, L-b-cyclohexylalanine, D-b-cyclohexylalanine, L-phenylglycine, D-phenylglycine, L-phenylalanine, D-phenylalanine, L-homophenylalanine, D-homophenylalanine, L-histidine, D-histidine, L-tryptophan, D-tryptophan, L-b-(2- thienyl)-alanine and D-b-(2-thienyl)-alanine; Yaa is a residue selected from glycine, L-alanine, D-alanine, 2-aminoisobutyric acid, L-a-aminobutyric acid, D-a-aminobutyric acid, L-norvaline, D-norvaline, L-norleucine, D-norleucine, L-cysteine, L-penicillamine, D-penicillamine, L-methionine, D-methionine, L-valine, D-valine, L-tert-butylglycine, D-tert-butylglycine, L-isoleucine, D-isoleucine, L-leucine, D-leucine, cyclohexylglycine, L-b-cyclohexylalanine, D-b-cyclohexylalanine, L-phenylglycine, D-phenylglycine, L-phenylalanine, D-phenylalanine, homophenylalanine, histidine, L-tryptophan, D-tryptophan, L-b-(2-thienyl)-alanine, and D-b-(2-thienyl)-alanine. AS can have the sequence: Bbs-Arg-(D-Pip) wherein Bbs is 4-tertbutylbenzenesulphonyl and D-Pip is D-pipecolic acid. P can have the sequence: Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-Cha- (D-Glu)-OH wherein Cha is b-cyclohexylalanine. A pharmaceutical composition thereof is useful for treating vascular diseases.
Patent NZ-506714-A (NZ)
Title: Concentrate 3 phase herbicidal composition
Inventor: AGBAJE HENRY E
IPC: A01N25/30
Filed: 1999-03-08
Abstract: A concentrate herbicidal composition comprising; a first herbicide selected from glyphosate and glufosinate; a second herbicide that is a chloroacetamide; and a third herbicide that is a triazine; where the composition is a suspoemulsion having an aqueous phase, an oil phase, and particles dispersed in the aqueous and/or oil phases, and is stabilized by an amount of one or more emulsifiers. Also described is a method of controlling weeds in a field, diluting the above herbicidal composition in a suitable volume of water in a spray tank to form a spray composition, and applying said spray composition at a time To by means of a sprayer fed from the spray tank to a soil surface in the field and to foliage of weeds that have emerged above the soil surface, whereby (i) the weeds are killed or controlled, and (ii) the emergence of weeds during a period of about 10 days immediately following To is inhibited.
Patent NZ-506910-A (NZ)
Title: Poultry shrink bags
Inventor: LIND KEITH D
IPC: B32B27/32
Filed: 1999-03-29
Abstract: A multiple layer polymeric film comprising a first and second layer, the composition of said first layer comprising a blend of ethylene vinyl acetate copolymer, linear low-density polyethylene, a second ethylene vinyl acetate copolymer and slip; the composition of said second layer comprising ethylene vinyl acetate copolymer; and a third layer comprising a blend of linear low density polyethylene and low density polyethylene said second layer being disposed between said first and third layer and wherein a colour concentrate may optionally and independently be present in layers one, two and three.
Patent NZ-509850-A (NZ)
Title: Carbon baking furnace
Inventor: LAZAROU RICK KIRIAKOS
IPC: F27B9/22
Filed: 1998-07-30
Abstract: A carbon baking furnace comprising a refractory lined kiln defining a baking path, further comprising a means for substantially continuously receiving green carbon articles, means for packing said green carbon articles in a sacrificial medium, a means for substantially continuously displacing the packed carbon articles through the said baking path and a means for substantially continuously removing baked carbon articles from the kiln.
Patent NZ-513065-A (NZ)
Title: Peptide fragments of MBP, their pharmaceutical compositions and their use in treating multiple sclerosis
Inventor: WARREN KENNETH G
IPC: A61K38/17
Filed: 1998-04-03
Abstract: A method of treating multiple sclerosis in a non-human patient is described. The method comprises administering to the non-human patient an effective amount of a peptide of the formula: Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr in admixture with a pharmaceutically acceptable carrier. This combination is used for the production of a medicament for neutralizing and modulating the production of anti-myelin basic protein. (62) Divided out of 338091
Patent NZ-515013-A (NZ)
Title: Process and apparatus for applying chemical papermaking additives to web substrate
Inventor: FICKE JONATHAN ANDREW
IPC: D21H25/08
Filed: 2000-05-02
Abstract: A process for applying a chemical additive, such as a softener, to a fibrous web comprises the steps of: providing a fibrous web having a first side and a second side opposite to the first side; providing a chemical additive; depositing the chemical additive only to the first side of the fibrous web; causing the first side of the fibrous web to contact the second side of the fibrous web thereby partially transferring the chemical additive from the first side to the second side of the fibrous web such that both the first side and the second side of the fibrous web comprise the chemical additive in a functionally sufficient amount. Preferably, the step of causing the two sides of the web to contact comprises winding the web into a roll.
Patent NZ-516246-A (NZ)
Title: Ethylene recovery system
Inventor: COLLING PHILIP M
IPC: C07C67/00
Filed: 2000-06-19
Abstract: A method for the recovery of ethylene from an inert gas purge stream from a reactor loop in a vapor-phase process for production of vinyl acetate comprising the steps of: Contacting the inert gas purge stream containing ethylene with acetic acid in an absorption vessel; Discharging a stream containing acetic acid and ethylene from one portion of the absorption vessel; Separating the ethylene from the acetic acid in the stream by contacting the stream with a recycle gas stream containing ethylene in a scrubber column; and Recovering ethylene from the scrubber column.
Patent NZ-520650-A (NZ)
Title: Improvements relating to radio communication systems
Inventor: BUSCH ADRIAN DAVID
IPC: H04L12/56
Filed: 2002-08-08
Abstract: A communications system includes a plurality of base station transceivers linked by a network backbone over which the base station transceivers communicate, a plurality of mobile transceivers adapted to communicate via the base station transceivers using macrodiversity, and wherein the mobile transceivers are further adapted to control allocation of system resources to enable communication.
Patent NZ-523100-A (NZ)
Title: A process for producing a carbohydrate composition
Inventor: ARCHER RICHARD HAMILTON
IPC: A23L33/20
Filed: 2002-12-10
Abstract: A process comprising the steps: (i) hydrolysis of lactose to produce glucose and galactose; (ii) partial isomerisation of the glucose to fructose; and (iii) partial oxidation of the glucose to gluconic acid; to produce a composition comprising a mixture of galactose, glucose, fructose, gluconic acid, unconverted lactose and non-lactose di- and oligo-saccharides without the need for any purification steps, a composition produced by the process and a food, such as a sports energy bar or sports drink, containing the composition.
Patent NZ-523805-A (NZ)
Title: Oncolytic virus
IPC: A61K35/76
Filed: 2000-09-18
Abstract: A modified vesicular stomatitis virus expressing a non-native protein on its surface which may be derived from a producer cell or may be a fusion protein comprising an affinity tag and a viral envelope protein.
Patent NZ-525436-A (NZ)
Title: Method and device for applying overcaps to aerosol cans
Inventor: KOVARA DANIEL L
IPC: B67B3/22
Filed: 2001-11-01
Abstract: A capping device and method for installing overcaps onto a plurality of aerosol cans moving on a manufacturing line is disclosed. The capping device has a pressure plate with a cap contact surface on one side and a bearing surface on an opposite side. The contact surface is oriented to face overcaps that are rested on a plurality of aerosol cans moving past the pressure plate on the manufacturing line. The contact surface is rotated about an axis so that an installation segment of the contact surface moves in concert with the plurality of aerosol cans. A pressure wheel has a rotatable circumferential surface arranged to bear against a part of the pressure plate to further bear the installation segment into contact with the overcaps of the plurality of aerosol cans. As the cans move past the pressure wheel and plate, the overcaps are installed on the aerosol cans by force applied via the installation segment of the contact surface that is moving along with the cans.
Patent NZ-525885-A (NZ)
Title: Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities
Inventor: CASTELHANO ARLINDO L
IPC: A61K/
Filed: 2001-11-30
Abstract: Compounds that specifically inhibit the adenosine A1, A2A, and A3 receptors and the use of these compounds to treat a disease associated with A1, A2A, and A3 adenosine receptors in a subject is disclosed, wherein: A1 adenosine receptor is associated with cognitive disease, renal failure, cardiac arrhythmias, respiratory epithelia, transmitter release, sedation, vasoconstriction, bradycardia, negative cardiac inotropy and dromotropy, branchoconstriction, neutropil chemotaxis, reflux condition, or ulcerative condition; A2A adenosine receptor is associated with locomotor activity, vasodilation, platelet inhibition, neutrophil superoxide generation, cognitive disorder, senile dementia, or Parkinson's disease; and A3 adenosine receptor is associated with glaucoma (for treating damage to the retinal or optic nerve head of the eye).